Welcome to BOPA
Latest news from BOPA
New Patient Safety Alert On Non-Luer Devices For SpinaL (intrathecal) Chemotherapy
A new Patient Safety Alert was issued yesterday concerning Non-Luer Devices for Spinal (Intrathecal) Chemotherapy. This guidance replaces that in previous Alerts concerning devices for chemotherapy. All other guidance in previous Alerts concerning other device types remains unchanged.
Please see link: http://www.england.nhs.uk/2014/02/20/psa-spinal-chemo
A Neuraxial Update Newsletter will be published shortly.
We hope to arrange the first meeting of the new Small Bore Connector Clinical Advisory Group in the next few months, terms of reference available in the BOPA Forum.
BOPA Announce Audit and Research Webinar - (Mon 10th March 2014)
BOPA are delighted to announce their first webinar of 2014, which will take place on Monday 10th March at 6pm.
Kumud Kantilal, was awarded a research fellowship by the NIHR Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London in 2013 to undertake a full-time Masters in Clinical Research and will present her experiences so far. She will provide tips on what the NIHR looks for in masters applicants and other NIHR funded programmes on offer.
The webinar will be chaired by Man-Chie Chow, joint-lead of the BOPA Audit and Research Committee.
How to register: Follow the instructions on the following link or email Simon Purcell (firstname.lastname@example.org) - https://bopa.webex.com/bopa/onstage/g.php?t=a&d=956030318
NHS England: Principles for sharing benefits with more efficient use of medicines
NHS England ‘Principles for sharing the benefits associated with more efficient use of medicines not reimbursed through national prices.’
Medicines Optimisation CRG for specialist services has supported the publication of the above document. The overarching aim for NHS England commissioned drugs (not covered by tariff) is that there is a move towards a consistent approach to gain sharing.
Any thoughts / comments / questions in relation to this document please send to Rob Duncombe. Robert.email@example.comRead More